Table 1 The correlation among CLDN6, SREBP1, and RAS expression and clinical features of patients with BC
From: CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation
Clinicopathologic features | CLDN6 | SREBP1 | RAS | ||||||
|---|---|---|---|---|---|---|---|---|---|
Low | High | P | Low | High | P | Low | High | P | |
Age | |||||||||
  ≤ 57 years | 18 | 5 | 0.73 | 12 | 11 | 0.179 | 12 | 11 | 0.283 |
  > 57 years | 20 | 7 | 9 | 18 | 10 | 17 | |||
Tumor size | |||||||||
  ≤ 3 cm | 23 | 7 | 0.892 | 13 | 17 | 0.815 | 15 | 15 | 0.295 |
  > 3 cm | 15 | 5 | 8 | 12 | 7 | 13 | |||
Pathology grade | |||||||||
 I–II | 18 | 5 | 0.73 | 8 | 15 | 0.34 | 11 | 12 | 0.615 |
 II–III | 20 | 7 | 13 | 14 | 11 | 16 | |||
Lymph node | |||||||||
 Negative | 16 | 10 | 0.013* | 12 | 14 | 0.536 | 12 | 14 | 0.749 |
 Positive | 22 | 2 | 9 | 15 | 10 | 14 | |||
Tumor stage | |||||||||
 0–IIA | 19 | 7 | 0.614 | 11 | 15 | 0.963 | 10 | 16 | 0.412 |
 IIB–III | 19 | 5 | 10 | 14 | 12 | 12 | |||